Brief: PepGen Announces Highest Mean Splicing Correction Reported In DM1 Patients
Sept 24 (Reuters) - PepGen Inc PEPG.O: PEPGEN ANNOUNCES HIGHEST MEAN SPLICING CORRECTION REPORTED IN DM1 PATIENTS PEPGEN: 53.7% MEAN SPLICING CORRECTION OBSERVED FOLLOWING SINGLE 15 MG/KG DOSE OF PGN-EDODM1, WITH ALL PATIENTS SHOWING IMPROVEMENT IN SPLICING PEPGEN: PGN-EDODM1 WAS GENERALLY WELL-TOLERATED AT 15 MG/KG, WITH DRUG-RELATED ADVERSE EVENTS MILD OR MODERATE IN SEVERITY Source text: ID:nBw4pPf7Ha Further company coverage: PEPG.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on PepGen
See all newsDyne, Sarepta shares tumble as Novartis setback weighs on muscle disease drug developers
PepGen Inc. reports results for the quarter ended June 30 - Earnings Summary
PepGen Q2 net loss narrows as expenses fall
Brief: PepGen Q2 EPS USD -0.26
PepGen Inc expected to post a loss of 29 cents a share - Earnings Preview